Market Cap 23.65B
Revenue (ttm) 3.81B
Net Income (ttm) -644.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 318.72
Profit Margin -16.92%
Debt to Equity Ratio 0.05
Volume 189,200
Avg Vol 468,388
Day's Range N/A - N/A
Shares Out 99.25M
Stochastic %K 82%
Beta 0.35
Analysts Strong Sell
Price Target $321.39

Company Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 61 685 19 00
Address:
Aeschengraben 27, 21st Floor, Basel, Switzerland
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:46 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $331.4, with an RSI of 29.42 indicating it is oversold. The stock is near its 60D low of $306.0, suggesting potential for a rebound. The MA30 at $334.72 and MA50 at $332.67 are close to the current price, indicating resistance levels. Directional Bias: Given the oversold RSI and proximity to the 60D low, we anticipate a bullish reversal. The ATR of 14.19 suggests volatility, which can provide trading opportunities. Trade Plan: - Suggested Entry: $331.4 - Stop Loss: $320.0 (3.9% below entry) - Take Profit Targets: - Target 1: $340.0 (2.6% gain) - Target 2: $350.0 (5.6% gain) - Target 3: $388.0 (17% gain) This plan allows for a favorable risk-reward ratio, aiming for a significant ROI on the third target. Monitor market conditions closely. https://privateprofiteers.com
0 · Reply
PrivateTrading
PrivateTrading Dec. 5 at 10:06 PM
$ONC I think that pirtobrutinib as a second line treatment will not do much if any harm to ONC. As a second line treatment, patients on Brukinsa would have to develop resistance then go to pirtobrutinib. If they develop resistance then they would be off Brukinsa anyway. One risk is if a doctor prescribes pirtobrutinib off-label as a first line treatment. But that action may not be best medical treatment because the risk would be if the CLL mutation did not work with the noncovalent pirtobrutinib then there would be no chance for a covalent treatment. The order of events has been to treat CLL/SLL with a covalent BTK inhibitor (Brukinsa, Calquence, Imbruvica) then if there is R/R to go to possibly a non-convalent (because it is reversible)
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Dec. 5 at 9:09 PM
$TGL Monday competing with $SMX and $ONC Past $CAPR WHAT A TREASURE LFG HOLDFORGOLD
0 · Reply
PrivateTrading
PrivateTrading Dec. 5 at 4:17 PM
$ONC I wonder if this morning's drop in price is due to the 12/3 FDA approval of pirtobrutinib for adults with r/r cll or sll who have previously been treated with a covalent inhibitor.
0 · Reply
albiegf13
albiegf13 Dec. 5 at 3:27 PM
0 · Reply
albiegf13
albiegf13 Dec. 4 at 4:31 PM
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:57 PM
$ONC $ONIT $ONLN $OPAL $OPEN Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 2 at 10:21 AM
$ONC Current Stock Price: $335.86 Contracts to trade: $340 ONC Dec 19 2025 Call Entry: $13.59 Exit: $23.81 ROI: 75% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 28 at 9:34 PM
$ONC Share Price: $340.82 Contract Selected: May 15, 2026 $340 Calls Buy Zone: $37.65 – $46.52 Target Zone: $60.05 – $73.40 Potential Upside: 51% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
albiegf13
albiegf13 Nov. 26 at 11:18 PM
$IBRX $ONC $AMGN WAFFLE HOUSE...
2 · Reply
Latest News on ONC
BeOne Medicines Continues To Execute In Q3

Dec 4, 2025, 1:11 PM EST - 1 day ago

BeOne Medicines Continues To Execute In Q3


BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:16 PM EST - 4 weeks ago

BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript


BeOne Medicines to Present at Upcoming Investor Conferences

Oct 28, 2025, 6:01 AM EDT - 5 weeks ago

BeOne Medicines to Present at Upcoming Investor Conferences


BeOne Medicines (ONC) Q2 EPS Soars 924%

Aug 6, 2025, 6:50 PM EDT - 4 months ago

BeOne Medicines (ONC) Q2 EPS Soars 924%


BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:36 PM EDT - 4 months ago

BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript


BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript

May 7, 2025, 2:04 PM EDT - 7 months ago

BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:46 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $331.4, with an RSI of 29.42 indicating it is oversold. The stock is near its 60D low of $306.0, suggesting potential for a rebound. The MA30 at $334.72 and MA50 at $332.67 are close to the current price, indicating resistance levels. Directional Bias: Given the oversold RSI and proximity to the 60D low, we anticipate a bullish reversal. The ATR of 14.19 suggests volatility, which can provide trading opportunities. Trade Plan: - Suggested Entry: $331.4 - Stop Loss: $320.0 (3.9% below entry) - Take Profit Targets: - Target 1: $340.0 (2.6% gain) - Target 2: $350.0 (5.6% gain) - Target 3: $388.0 (17% gain) This plan allows for a favorable risk-reward ratio, aiming for a significant ROI on the third target. Monitor market conditions closely. https://privateprofiteers.com
0 · Reply
PrivateTrading
PrivateTrading Dec. 5 at 10:06 PM
$ONC I think that pirtobrutinib as a second line treatment will not do much if any harm to ONC. As a second line treatment, patients on Brukinsa would have to develop resistance then go to pirtobrutinib. If they develop resistance then they would be off Brukinsa anyway. One risk is if a doctor prescribes pirtobrutinib off-label as a first line treatment. But that action may not be best medical treatment because the risk would be if the CLL mutation did not work with the noncovalent pirtobrutinib then there would be no chance for a covalent treatment. The order of events has been to treat CLL/SLL with a covalent BTK inhibitor (Brukinsa, Calquence, Imbruvica) then if there is R/R to go to possibly a non-convalent (because it is reversible)
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Dec. 5 at 9:09 PM
$TGL Monday competing with $SMX and $ONC Past $CAPR WHAT A TREASURE LFG HOLDFORGOLD
0 · Reply
PrivateTrading
PrivateTrading Dec. 5 at 4:17 PM
$ONC I wonder if this morning's drop in price is due to the 12/3 FDA approval of pirtobrutinib for adults with r/r cll or sll who have previously been treated with a covalent inhibitor.
0 · Reply
albiegf13
albiegf13 Dec. 5 at 3:27 PM
0 · Reply
albiegf13
albiegf13 Dec. 4 at 4:31 PM
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:57 PM
$ONC $ONIT $ONLN $OPAL $OPEN Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 2 at 10:21 AM
$ONC Current Stock Price: $335.86 Contracts to trade: $340 ONC Dec 19 2025 Call Entry: $13.59 Exit: $23.81 ROI: 75% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 28 at 9:34 PM
$ONC Share Price: $340.82 Contract Selected: May 15, 2026 $340 Calls Buy Zone: $37.65 – $46.52 Target Zone: $60.05 – $73.40 Potential Upside: 51% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
albiegf13
albiegf13 Nov. 26 at 11:18 PM
$IBRX $ONC $AMGN WAFFLE HOUSE...
2 · Reply
MaverikIT
MaverikIT Nov. 26 at 2:46 PM
$CELC +2.12 - eyeing another 52wk$ $GRAL $ONC ...
0 · Reply
notreload_ai
notreload_ai Nov. 26 at 12:07 PM
The FDA has accepted and fast-tracked $ONC new drug sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, a rare and fast-growing blood cancer. https://notreload.xyz/fda-fast-tracks-beone-sonrotoclax-for-mcl-treatment/
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 26 at 11:57 AM
WATCHLIST NOV 26 2025 $KURA Kura Oncology And Kyowa Kirin Announce NCCN Inclusion Of Newly FDA-Approved KOMZIFTI As Recommended Treatment For Relapsed/Refractory AML With NPM1 Mutation $OMSE OMS Energy Technologies Says Indonesian Subsidiary Achieves API Spec 11D1 Certification; Company Expands Self-Manufactured Packer Product Portfolio $RNW Suncoast Charging Opens First Tesla V4 325 kW DC Fast Charging Station At Hub At Bexley In Land O'Lakes Florida, Plans Around 20 New Stations In 2026 And Names David Patrick Co Founder $ONC BeOne Medicines Receives US FDA Priority Review For Sonrotoclax In Relapsed Or Refractory Mantle Cell Lymphoma After BTK Inhibitor Therapy $CVEO Civeo Enters Cooperation Agreement With Engine Capital And Appoints Jeffrey B. Scofield And Daniel B. Silvers To Board Of Directors
1 · Reply
SuperGreenToday
SuperGreenToday Nov. 25 at 7:16 PM
$ONC Share Price: $336.90 Contract Selected: May 15, 2026 $340 Calls Buy Zone: $35.79 – $44.21 Target Zone: $66.83 – $81.68 Potential Upside: 76% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
albiegf13
albiegf13 Nov. 25 at 5:41 PM
1 · Reply
pilobious
pilobious Nov. 24 at 6:35 PM
$ONC lots of strange movement on this today. Can’t find any news that would cause it.
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 5:52 PM
Truist Securities updates rating for BeOne Medicines ( $ONC ) to Buy, target set at 400.
0 · Reply
notreload_ai
notreload_ai Nov. 24 at 1:53 PM
$MRK , $ONC , $MGTX , $MNKD , $FULC ... Wells Fargo upgrades Merck to Overweight; Truist and H.C. Wainwright initiate coverage on BeOne Medicines, MeiraGTx, MannKind, and Fulcrum with Buy ratings and promising price targets. https://notreload.xyz/merck-beone-meiragtx-mannkind-fulcrum-updates/
0 · Reply
albiegf13
albiegf13 Nov. 23 at 8:59 PM
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:42 PM
0 · Reply
BigWaveTrading
BigWaveTrading Nov. 22 at 10:13 AM
$XLV Continues To Lead With The Overall Market Under Red-Flag Conditions; Two New Swing Setups In this video I review the overall market, the leadership in Medical/Biotech names, and two new long positions I am entering on Monday. $JAZZ $ONC $XBI https://www.youtube.com/watch?v=8WXLvnua8-E
0 · Reply
albiegf13
albiegf13 Nov. 20 at 2:22 PM
1 · Reply